Properties
What is it?
Composition: Active ingredients: Dequalinium chloride, Dibucaine hydrochloride; 1 lozenge contains Dequalinium chloride 0.25 mg (calculated on 100% substance), Dibucaine hydrochloride 0.03 mg (calculated on 100% substance); Excipients: Mint and lemon flavored tablets: Sorbitol (E 420), Talc, Colloidal anhydrous silica, Magnesium stearate, Lemon flavor, Bitter mint oil. Dosage form. Lozenges. Main physicochemical properties: White round tablets with a bevel on both sides and a dividing line on one side. Pharmacotherapeutic group: Preparations for throat diseases. Indications: Local treatment of acute inflammatory diseases of the oral cavity and throat: gingivitis, ulcerative and aphthous stomatitis, tonsillitis, laryngitis and pharyngitis. Laritilen is also recommended for bad breath. Laritilen can be used in cases of mixed oral and pharyngeal infections (on doctor's recommendation); as an adjunct in the treatment of catarrhal angina, lacunar angina and Plaut-Vincent angina; in cases of oral and pharyngeal candidiasis. Recommended in the postoperative period after tonsillectomy and tooth extraction. Contraindications: Hypersensitivity to any of the components of the preparation. Allergy to quaternary ammonium compounds (e.g., benzalkonium chloride). Special precautions: Since the preparation does not contain sugar, it is suitable for use in patients with diabetes mellitus. The preparation contains sorbitol, therefore it should not be used in patients with rare hereditary diseases such as fructose intolerance syndrome. Patients with low cholinesterase levels in blood plasma should use with caution. Use during pregnancy and lactation: Pregnancy: To date, no controlled studies have been conducted. In these circumstances, the preparation can be used during pregnancy after consulting a doctor, if the therapeutic effect outweighs the potential risk to the fetus. Lactation: To date, no clinical studies have been conducted on the penetration of active substances into breast milk. Use of the preparation during lactation is not recommended. Method of administration and dosage: Adults and children over 12 years of age: 1 tablet every 2 hours, after reduction of inflammatory symptoms - 1 tablet every 4 hours. Children over 4 years of age: 1 tablet every 3 hours, after reduction of inflammatory symptoms - 1 tablet every 4 hours. The maximum daily dose is 10-12 tablets during the acute phase and 6 tablets after the inflammatory symptoms subside. Tablets should be dissolved slowly in the mouth, without chewing. The duration of the treatment course is determined individually by the doctor. If symptoms do not subside or worsen after 5 days of treatment, the patient should consult a doctor. Children. The preparation in this dosage form is not prescribed for children under 4 years of age. Side effects: After using the preparation, hypersensitivity reactions may sometimes occur, e.g., rash, itching, burning sensation, irritation of the mucous membranes of the oral cavity and throat. In rare cases, especially with misuse, ulceration and necrosis may develop. If any unusual reactions occur, the use of the preparation should be discontinued and a doctor should be consulted for further therapy.